200 related articles for article (PubMed ID: 28109626)
1. Significance of lymph node metastasis on survival of women with uterine adenosarcoma.
Machida H; Nathenson MJ; Takiuchi T; Adams CL; Garcia-Sayre J; Matsuo K
Gynecol Oncol; 2017 Mar; 144(3):524-530. PubMed ID: 28109626
[TBL] [Abstract][Full Text] [Related]
2. Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study.
Seagle BL; Kanis M; Strohl AE; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):636-641. PubMed ID: 27771166
[TBL] [Abstract][Full Text] [Related]
3. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
[TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.
Goff BA; Rice LW; Fleischhacker D; Muntz HG; Falkenberry SS; Nikrui N; Fuller AF
Gynecol Oncol; 1993 Jul; 50(1):105-9. PubMed ID: 8349151
[TBL] [Abstract][Full Text] [Related]
5. Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma.
Nasioudis D; Chapman-Davis E; Frey M; Holcomb K
J Gynecol Oncol; 2017 Jul; 28(4):e46. PubMed ID: 28541635
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of adenosarcoma and the inverse probability of treatment weighting (IPTW) adjusted survival analysis of lymph node dissection in uterine adenosarcoma.
Hu H; Wei Z; Zhao H; Yuan G
Medicine (Baltimore); 2022 Sep; 101(38):e30607. PubMed ID: 36197202
[TBL] [Abstract][Full Text] [Related]
7. Cluster of uterine mullerian adenosarcoma in the Washington, DC metropolitan area with high incidence of sarcomatous overgrowth.
Seidman JD; Wasserman CS; Aye LM; MacKoul PJ; O'Leary TJ
Am J Surg Pathol; 1999 Jul; 23(7):809-14. PubMed ID: 10403304
[TBL] [Abstract][Full Text] [Related]
8. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
9. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes.
Nathenson MJ; Conley AP; Lin H; Fleming N; Lazar A; Wang WL; Ravi V
Int J Gynecol Cancer; 2018 Sep; 28(7):1297-1310. PubMed ID: 30044322
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma.
Amant F; Schurmans K; Steenkiste E; Verbist L; Abeler VM; Tulunay G; De Jonge E; Massuger L; Moerman P; Vergote I
Gynecol Oncol; 2004 Jun; 93(3):680-5. PubMed ID: 15196864
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in patients with uterine sarcoma: the SARCUT study.
Zapardiel I; Gracia Segovia M; Macuks R; Mancari R; Achimas-Cadariu P; Corrado G; Bartusevicius A; Sukhin V; Muruzabal JC; Coronado MartÃn PJ; Gardella B; Piek JM; Concin N; Arab C; Papatheodorou D; Polterauer S; Iacoponi S; Nieto T; Lopez-Sanclemente MC; Trukhan H; Gil MM; Bakinovskaya I; Dalamanava A; Cucurull M; Rovski D; Baquedano L; Chiva L; Mardas M; Mavrichev SA; Klat J; Lopez de la Manzanara CA; Yildirim Y;
Int J Gynecol Cancer; 2023 Jun; 33(6):897-904. PubMed ID: 37192761
[TBL] [Abstract][Full Text] [Related]
12. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.
Le Page C; Almadani N; Turashvili G; Bataillon G; Portelance L; Provencher D; Mes-Masson AM; Gilks B; Hoang L; Rahimi K
Int J Gynecol Pathol; 2021 Sep; 40(5):487-494. PubMed ID: 33720083
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for uterine adenosarcoma: a review.
Nathenson MJ; Conley AP
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1093-1100. PubMed ID: 30169984
[TBL] [Abstract][Full Text] [Related]
14. Metastasizing uterine mullerian adenosarcoma in a young female: Diagnostic enigma.
Patnayak R; Rukmangadha N; Architha P; Reddy GS; Lakshmi AY; Kannan T; Jena A
Indian J Pathol Microbiol; 2018; 61(3):440-442. PubMed ID: 30004077
[TBL] [Abstract][Full Text] [Related]
15. Mullerian adenosarcoma of the female genital tract.
McCluggage WG
Adv Anat Pathol; 2010 Mar; 17(2):122-9. PubMed ID: 20179434
[TBL] [Abstract][Full Text] [Related]
16. Synovial Sarcoma Is Not Associated With a Higher Risk of Lymph Node Metastasis Compared With Other Soft Tissue Sarcomas.
Jacobs AJ; Morris CD; Levin AS
Clin Orthop Relat Res; 2018 Mar; 476(3):589-598. PubMed ID: 29529647
[TBL] [Abstract][Full Text] [Related]
17. Staging of uterine sarcomas.
Tse KY; Crawford R; Ngan HY
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):733-49. PubMed ID: 21752716
[TBL] [Abstract][Full Text] [Related]
18. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence.
Carroll A; Ramirez PT; Westin SN; Soliman PT; Munsell MF; Nick AM; Schmeler KM; Klopp AH; Fleming ND
Gynecol Oncol; 2014 Dec; 135(3):455-61. PubMed ID: 25449308
[TBL] [Abstract][Full Text] [Related]
19. Site-specific factors for cancer of the corpus uteri from SEER registries: collaborative stage data collection system, version 1 and version 2.
Jamison PM; Altekruse SF; Chang JT; Zahn J; Lee R; Noone AM; Barroilhet L
Cancer; 2014 Dec; 120 Suppl 23():3836-45. PubMed ID: 25412395
[TBL] [Abstract][Full Text] [Related]
20. Role of lymphadenectomy for apparent early stage uterine sarcoma; a comprehensive analysis of the National Cancer Database.
Nasioudis D; Mastroyannis SA; Latif NA; Ko EM; Haggerty AF; Kim SH; Morgan MA; Giuntoli RL
Surg Oncol; 2021 Sep; 38():101589. PubMed ID: 33957499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
